Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Adrenoleukodystrophy epidemiology and demographics

Introduction

Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.

Overview

Overview

Adrenoleukodystrophy is the most common peroxisomal disorder, with an estimated incidence of 1 in 17,000 births (male and female) and 1 in 21,000 males in the United States. The prevalence of X-linked adrenoleukodystrophy is approximately 1 in 20,000 individuals. This condition occurs with a similar frequency in all populations. The lifetime prevalence of adrenal insufficiency in ALD is ~80%.

Epidemiology and Demographics

Epidemiology and Demographics

Incidence

  • Adrenoleukodystrophy is the most common peroxisomal disorder, with an estimated incidence of 1 in 17,000 births (male and female) and 1 in 21,000 males in the United States. [1]

Prevalence

  • The prevalence of X-linked adrenoleukodystrophy is approximately 1 in 20,000 individuals. This condition occurs with a similar frequency in all populations.
  • The lifetime prevalence of adrenal insufficiency in ALD is ~80%. [2]

Age

  • Childhood cerebral type commonly occurs in 3-10 years of age.[3]
  • AMN type has a median age of 28 years.[3]
  • Addison disease type occurs in 0 to (greater or equal to) 10 years of age.[3]
  • Cerebellar type can occur in childhood or adolescence.

Race

There is no racial predilection to adrenoleukodystrophy.

Gender

  • Men are more commonly affected by adrenoleukodystrophy than women. However, women can be a carrier of the disease.
References

References

  1. ↑ Wiens K, Berry SA, Choi H, Gaviglio A, Gupta A, Hietala A; et al. (2019). “A report on state-wide implementation of newborn screening for X-linked Adrenoleukodystrophy”. Am J Med Genet A. 179 (7): 1205–1213. doi:10.1002/ajmg.a.61171. PMC 6619352 Check |pmc= value (help). PMID 31074578.
  2. ↑ Huffnagel, Irene C; Laheji, Fiza K; Aziz-Bose, Razina; Tritos, Nicholas A; Marino, Rose; Linthorst, Gabor E; Kemp, Stephan; Engelen, Marc; Eichler, Florian (2019). “The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy: An International Collaboration”. The Journal of Clinical Endocrinology & Metabolism. 104 (1): 118–126. doi:10.1210/jc.2018-01307. ISSN 0021-972X.
  3. ↑ 3.0 3.1 3.2 Moser HW, Raymond GV, Dubey P (2005). “Adrenoleukodystrophy: new approaches to a neurodegenerative disease”. JAMA. 294 (24): 3131–4. doi:10.1001/jama.294.24.3131. PMID 16380594.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: